AU2022253888B2 - Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin - Google Patents

Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin

Info

Publication number
AU2022253888B2
AU2022253888B2 AU2022253888A AU2022253888A AU2022253888B2 AU 2022253888 B2 AU2022253888 B2 AU 2022253888B2 AU 2022253888 A AU2022253888 A AU 2022253888A AU 2022253888 A AU2022253888 A AU 2022253888A AU 2022253888 B2 AU2022253888 B2 AU 2022253888B2
Authority
AU
Australia
Prior art keywords
met
nsclc
subject
squamous
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022253888A
Other languages
English (en)
Other versions
AU2022253888A1 (en
AU2022253888A9 (en
Inventor
Janet Yikai JIN
Philip B. Komarnitsky
Mirella Lazarov
Anita Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbvie Manufacturing Management ULC
Original Assignee
Abbvie Manufacturing Management ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Manufacturing Management ULC filed Critical Abbvie Manufacturing Management ULC
Publication of AU2022253888A1 publication Critical patent/AU2022253888A1/en
Publication of AU2022253888A9 publication Critical patent/AU2022253888A9/en
Assigned to AbbVie Manufacturing Management Unlimited Company reassignment AbbVie Manufacturing Management Unlimited Company Request for Assignment Assignors: ABBVIE BIOTHERAPEUTICS INC.
Application granted granted Critical
Publication of AU2022253888B2 publication Critical patent/AU2022253888B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2022253888A 2021-04-06 2022-04-06 Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin Active AU2022253888B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163171571P 2021-04-06 2021-04-06
US202163171536P 2021-04-06 2021-04-06
US63/171,571 2021-04-06
US63/171,536 2021-04-06
PCT/US2022/023629 WO2022216796A1 (en) 2021-04-06 2022-04-06 Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin

Publications (3)

Publication Number Publication Date
AU2022253888A1 AU2022253888A1 (en) 2023-09-28
AU2022253888A9 AU2022253888A9 (en) 2024-02-22
AU2022253888B2 true AU2022253888B2 (en) 2026-04-30

Family

ID=83510391

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022253888A Active AU2022253888B2 (en) 2021-04-06 2022-04-06 Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin

Country Status (8)

Country Link
US (1) US12433951B2 (cg-RX-API-DMAC7.html)
EP (1) EP4319811A1 (cg-RX-API-DMAC7.html)
JP (1) JP7905040B2 (cg-RX-API-DMAC7.html)
AU (1) AU2022253888B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023020562A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214989A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011733A (cg-RX-API-DMAC7.html)
WO (1) WO2022216796A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024276234A1 (en) * 2023-05-23 2025-12-04 AbbVie Manufacturing Management Unlimited Company Methods of treatment using anti-c-met antibody drug conjugates
WO2026125722A1 (en) * 2024-12-12 2026-06-18 AbbVie Manufacturing Management Unlimited Company Purified forms of teliso-v

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200215200A1 (en) * 2016-05-17 2020-07-09 Abbvie Inc. ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
WO2010064089A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Novel anti-cmet antibody
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2402370A1 (en) 2010-06-29 2012-01-04 Pierre Fabre Médicament Novel antibody for the diagnosis and/or prognosis of cancer
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
EP3856783A1 (en) 2018-09-26 2021-08-04 Genmab A/S Axl-specific antibodies for treatment of non-small cell lung cancer
WO2021007428A2 (en) * 2019-07-09 2021-01-14 The Johns Hopkins University Molecules, compositions and methods for treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200215200A1 (en) * 2016-05-17 2020-07-09 Abbvie Inc. ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE

Also Published As

Publication number Publication date
MX2023011733A (es) 2023-10-13
AU2022253888A1 (en) 2023-09-28
AU2022253888A9 (en) 2024-02-22
JP7905040B2 (ja) 2026-08-14
US12433951B2 (en) 2025-10-07
BR112023020562A2 (pt) 2023-12-05
EP4319811A1 (en) 2024-02-14
WO2022216796A1 (en) 2022-10-13
CA3214989A1 (en) 2022-10-13
JP2024514506A (ja) 2024-04-02
US20220323597A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
CN103747802B (zh) 用于增加folr1癌症治疗的功效的方法
US10241115B2 (en) Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
JP6057718B2 (ja) ベバシズマブ併用治療のための腫瘍組織に基づくバイオマーカー
KR20230118713A (ko) 종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
JP2021534188A (ja) NaPi2bに標的指向されたポリマー抗体−薬物コンジュゲートおよびその使用方法
CN105814079A (zh) 用于检测叶酸受体1的抗体和测定
KR20260015178A (ko) 항-c-met 항체 약물 접합체를 이용한 치료 방법
CN104364651A (zh) 用于增加基于cd37的疗法的功效的方法
US20130115628A1 (en) Method for selection of chemotherapeutic agents for adenocarcinoma cancer
US12433951B2 (en) Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin
JP6383787B2 (ja) 卵巣癌の治療方法
CN107624071A (zh) 肺癌治疗方法
JP6122948B2 (ja) 胃癌の治療のための方法
US20230285394A1 (en) Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertinib
JP7695672B2 (ja) 癌の予後バイオマーカー
CN117136072A (zh) 使用维汀-特立妥珠单抗治疗非小细胞肺癌的方法
US20250189528A1 (en) Biomarkers for disease progression and/or recurrence in squamous cell carcinoma
JP2025516878A (ja) 抗clever-1治療の恩恵を受けるがん患者を同定する方法
JP2025516877A (ja) 抗clever-1治療の恩恵を受けるがん患者を同定する方法
Deshpande et al. MA 06.03 Programmed Death-Ligand 1 (PD-L1) Expression in Clinical Practice: Comparison of Temporally or Spatially Separated Test Results
EA041061B1 (ru) Способы идентификации рака как с вероятностью реагирующего на анти-folr1 иммуноконъюгат

Legal Events

Date Code Title Description
SREP Specification republished
PC1 Assignment before grant (sect. 113)

Owner name: ABBVIE MANUFACTURING MANAGEMENT UNLIMITED COMPANY

Free format text: FORMER APPLICANT(S): ABBVIE BIOTHERAPEUTICS INC.